Quantcast
Home > Quotes > PRAN
PRAN

Prana Biotechnology Ltd American Depositary Shares (PRAN) Quote & Summary Data

$1.64
*  
0.0283
1.7%
Get PRAN Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading PRAN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
4
Today's High / Low
$ 1.7499 / $ 1.60
Share Volume
12,385
50 Day Avg. Daily Volume
31,012
Previous Close
$ 1.6683
52 Week High / Low
$ 3.79 / $ 1.56
Market Cap
14,677,318
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.07

Intraday Chart

Shares Traded

Share Volume:
12,385
50 Day Avg. Daily Volume:
31,012

Trading Range

The current last sale of $1.64 is 5.13% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.7499 $ 3.79
 Low: $ 1.60 $ 1.56

Company Description (as filed with the SEC)

Our legal and commercial name is Prana Biotechnology Limited. We were incorporated under the laws of the Commonwealth of Australia on November 11, 1997 and began limited operations shortly thereafter. Our registered office is located at Level 3, 62 Lygon Street, Carlton, Victoria, 3053, Australia and our telephone number is 011-61-3-9824-5254. Our principal executive office is located at Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia and our telephone number is 011-61-3-9349-4906. Our website address is www.pranabio.com. The information in our website is not incorporated by reference into this annual report. Our mission is to develop therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. While we historically focused on drugs targeting Alzheimer's disease and Huntington disease, we are presently concentrating our efforts on drugs targeting Parkinsonian diseases.  ... More ...  


Risk Grade

Where does PRAN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.66
Open Date:
Nov. 16, 2018
Close Price:
$ 1.66
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x